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Abstract
Background: In a previous study PCR analysis of clinical samples from suspected cases of Buruli ulcer disease (BUD) from
Togo and external quality assurance (EQA) for local microscopy were conducted at an external reference laboratory in
Germany. The relatively poor performance of local microscopy as well as effort and time associated with shipment of PCR
samples necessitated the implementation of stringent EQA measures and availability of local laboratory capacity. This study
describes the approach to implementation of a national BUD reference laboratory in Togo.
Methodology: Large scale outreach activities accompanied by regular training programs for health care professionals were
conducted in the regions ‘‘Maritime’’ and ‘‘Central,’’ standard operating procedures defined all processes in participating
laboratories (regional, national and external reference laboratories) as well as the interaction between laboratories and
partners in the field. Microscopy was conducted at regional level and slides were subjected to EQA at national and external
reference laboratories. For PCR analysis, sample pairs were collected and subjected to a dry-reagent-based IS2404-PCR (DRB-
PCR) at national level and standard IS2404 PCR followed by IS2404 qPCR analysis of negative samples at the external
reference laboratory.
Principal Findings: The inter-laboratory concordance rates for microscopy ranged from 89% to 94%; overall, microscopy
confirmed 50% of all suspected BUD cases. The inter-laboratory concordance rate for PCR was 96% with an overall PCR case
confirmation rate of 78%. Compared to a previous study, the rate of BUD patients with non-ulcerative lesions increased from
37% to 50%, the mean duration of disease before clinical diagnosis decreased significantly from 182.6 to 82.1 days among
patients with ulcerative lesions, and the percentage of category III lesions decreased from 30.3% to 19.2%.
Conclusions: High inter-laboratory concordance rates as well as case confirmation rates of 50% (microscopy), 71% (PCR at
national level), and 78% (including qPCR confirmation at external reference laboratory) suggest high standards of BUD
diagnostics. The increase of non-ulcerative lesions, as well as the decrease in diagnostic delay and category III lesions, prove
the effect of comprehensive EQA and training measures involving also procedures outside the laboratory.
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Introduction
Buruli ulcer disease (BUD), caused by Mycobacterium ulcerans, is
an infectious disease affecting skin, soft tissue and bones. If left
untreated, extensive destruction of tissue followed by fibrous
scarring and contractures may lead to severe functional limitations
[1–6]. BUD is treated with rifampicin and streptomycin (or
clarithromycin) for eight weeks if necessary followed by surgical
interventions; the laboratory confirmation of clinically suspected
BUD cases prior to treatment has become an integral part of
clinical management. Whereas microscopy is an appropriate and
cost-effective first-line test for peripheral laboratories, PCR is
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considered the method of choice and WHO recommends PCR
confirmation of at least 50% of suspected BUD cases [3,7–13].
Microscopy and various PCR assays have been successfully
implemented in other endemic countries and case confirmation
rates of 29–78% (microscopy) and 54–83% (PCR) were reported
[10,12–32].
Since the early 1990s, close to 2,000 BUD cases were reported
from Togo. However, due to the lack of local diagnostic laboratory
capacity, the majority of these cases remained unconfirmed
[7,13,33–35].
From 2007 through 2010, a joint research project between the
German Leprosy and Tuberculosis Relief Organization, Togo
office, Lome´, Togo (DAHWT) and the Department of Infectious
Diseases and Tropical Medicine (DITM), University Hospital,
Ludwig-Maximilians-University, Munich, Germany, allowed the
first systematic study on laboratory confirmation of BUD cases
from Togo and proved the prevalence of BUD in South Togo
(region ‘‘Maritime’’). The study revealed a relatively poor
performance of local Ziehl-Neelsen microscopy, suggesting the
need for a stringent system for external quality assurance (EQA)
including regular supervision of microscopy laboratories. Intensi-
fied training measures in the area of sample collection resulted in a
PCR case confirmation rate of 70%. Effort and turnaround time
associated with shipment of samples to an external reference
laboratory, however, necessitated the availability of local labora-
tory capacities [13].
In the context of the EC-funded research project ‘‘BuruliVac’’
(FP7/2010–2013; grant agreement Nu 241500), the implementa-
tion of a national reference laboratory for BUD in Togo was
envisaged. Therefore, from January 2011 through April 2012,
microscopy and PCR facilities were established at the ‘‘Institut
National d’Hygie`ne’’ (INH), Lome´, Togo.
This study describes the approach to implementation of a
national reference laboratory and analyzes the impact of
intensified EQA and training measures on laboratory diagnosis
and control of BUD in Togo.
Materials and Methods
Ethics
Ethical clearance was obtained through the national Togolese
ethics committee (‘‘Comite´ de Bioe´thique pour la Recherche en
Sante´’’) at the University of Lome´ (14/2010/CBRS) and the study
was approved by the ‘‘Ministe`re de la Sante´ de la Re´publique
Togolaise’’ Lome´, Togo (Ref. No. 0009/2011/MS/DGS/DPLET).
All samples analyzed in this study were collected for diagnostic
purposes within the EC funded research project ‘‘BuruliVac’’.
Written informed consent was obtained from all study participants.
Role of participating institutions
This study constitutes a collaborative project between several
Togolese and German institutions. Since 2007, the German
Leprosy and Tuberculosis Relief Organization (DAHW) has
supported the Togolese National Buruli Ulcer Control Program
(‘‘Programme National de Lutte contre L’Ulce`re de Buruli – Le`pre
et Pian’’ [PNLUB-LP]) in the area of training, laboratory
confirmation and treatment of BUD. In this study, the main tasks
of DAHWT, as partner of the ‘‘BuruliVac’’ consortium were field
work, recruitment of study participants, and collection of
diagnostic samples. The tasks of DITM – an accredited laboratory
according to DIN EN ISO 15189 - as lead partner for all patient
related activities of the ‘‘BuruliVac’’ project consisted of imple-
mentation of molecular diagnostic laboratory methods at the
designated national Togolese BUD reference laboratory and
standardization of all processes through on-site training, standard
operating procedures (SOPs), and EQA of microscopy and PCR
(by standard gel-based IS2404 PCR and IS2404 quantitative real-
time PCR [qPCR]) including supervisory visits. Patients with
suspected BUD were referred to peripheral health posts (‘‘Unite´ de
Soins Pe´riphe´rique’’, USP; operating on district level as point of
care facilities with a catchment area of 5,000–9,000 inhabitants
depending on the number of facilities per district), or a regional
hospital (‘‘Centre Hospitalier Re´gional [CHR] de Tse´vie´’’, region
‘‘Maritime’’, Togo, since 2007 national reference centre for BUD
in Togo; catchment area: 2,599,955 inhabitants) for diagnosis and
treatment; CHR conducted microscopic analysis. The ‘‘Institut
National d’Hygie`ne’’ (INH), Lome´, Togo – a laboratory accredited
by COFRAC (‘‘Comite´ Franc¸ais d’Accre´ditation’’) according to NF
EN ISO/CEI 17025 (version 2005) – constitutes the national
Togolese reference laboratory for surveillance of transmissible,
especially outbreak prone diseases, and has been nominated national
reference laboratory for Buruli ulcer disease in 2010 [13]. In this
study, INH resumed EQA for microscopy conducted at regional
level and – after installation of a BUD PCR laboratory – PCR
assessment of diagnostic samples by means of a dry-reagent-based
PCR [21,25,29]. In March 2011, INH joined the WHO network for
laboratory confirmation of BUD and – like DITM – participates in
the annual program for external quality assessment of molecular
detection of M. ulcerans in clinical specimens provided by the
Mycobacteriology Unit, Microbiology Department, Institute for
Tropical Medicine, Antwerp, Belgium, WHO Collaborating Centre
for the diagnosis and surveillance of M. ulcerans infection [36].
Study area and implementation of outreach programs
In each of the six districts (Golfe, Ave, Zio, Yoto, Vo, Lac) of the
region ‘‘Maritime’’, five districts (‘‘Direction de District Sanitaire’’
[DDS] 1–5) of the region ‘‘Lome´ Commune’’ where BUD was
proven to be endemic [13] and the four districts of the region
‘‘Central’’ (Blitta, Sotouboua, Tchaoudjo, Thamba), where BUD
has been assumed to be endemic, outreach teams (‘‘CLT teams’’)
consisting of district controllers (‘‘Controˆleur Le`pre-TB-Buruli’’,
Author Summary
Buruli ulcer disease (BUD), the third most common
mycobacterial disease worldwide, is treated with stan-
dardized antimycobacterial therapy. According to WHO
recommendations at least 50% of cases should be
laboratory confirmed by polymerase chain reaction (PCR).
In a previous study PCR analysis of clinical samples from
suspected BUD cases from Togo and external quality
assurance (EQA) for local microscopy were conducted at
an external reference laboratory in Germany. The relatively
poor performance of local microscopy as well as time and
effort associated with shipment of clinical samples abroad
necessitated the availability of a local BUD reference
laboratory and the implementation of stringent EQA
measures. All processes in the laboratories as well as in
the field were defined by standard operating procedures,
microscopy conducted at regional facilities was subjected
to EQA at national and external reference level, and PCR
samples were analyzed in parallel at national and external
reference laboratories. Inter-laboratory concordance rates
of .90% and case confirmation rates of 50% (microscopy)
and .70% (PCR) respectively suggest high standards of
BUD diagnostics. Furthermore, an increase of non-ulcera-
tive lesions and a decrease in diagnostic delay and
category III lesions reflect the impact of comprehensive
EQA measures also involving procedures outside the
laboratory on the quality of BUD control.
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CLT), USP staff (‘‘Infirmie`re du Centre Peripherique’’, ICP) and
community health workers (‘‘Agent de Sante´ Communautaire’’,
ASC), and village nurses were formed and trained by experienced
PNLUB-LP, CHR, DITM and DAHW staff. The main tasks of
the CLT teams are supervision of USPs, as well as sensitization
and screening activities in the field which are mostly conducted
under participation of DAHW and CHR staff and in collaboration
with PNLUB-LP and the non-governmental organization Hand-
icap International. In particular the ASCs who are trained and
continuously supervised by the respective CLTs constitute an
integral part of the outreach activities. They organize quarterly
sensitization activities and present educational films and information
material in villages within proven or assumed areas of endemicity.
Villagers are instructed to report to their local ASCs in case of
wounds or other lesions suspicious for BUD, thus ASCs represent the
primary contact person for the population on community level.
Furthermore, ASCs organize regular screening programs in village
schools to identify suspected BUD cases in the field. The final
decision on referral of suspected BUD cases to USPs or CHR for
further diagnosis and treatment lies with a superordinate ‘‘BUD
team’’ consisting of medical staff (physician, nurse) from CHR,
ASCs, and the regional CLT. Visits to field sites are conducted on
demand of district CLT teams according to a schedule elaborated by
the ASCs. A routine reporting system between ASCs, ICPs, CLTs
and CHR staff has been established and to facilitate communication
within and between CLT teams and BUD teams a mobile phone
network has been implemented by DAHW in 2010.
Data management
Data collection was conducted by means of the WHO ‘‘BU01’’
form [3] and standardized project specific laboratory data entry
forms (Form S1). All clinical, epidemiological and laboratory data
including EQA results were entered in a web-based database
specifically designed for the ‘‘BuruliVac’’ project.
Sample collection
Diagnostic samples were collected according to standardized
procedures. Briefly, swabs were collected by circling the entire
undermined edges of ulcerative lesions. Three millimeter punch
biopsies and fine needle aspirates (FNA) were collected from the
center of non-ulcerative lesions or from undermined edges of
ulcerative lesions including necrotic tissue. To facilitate sampling,
standardized specimen collection bags including swabs, biopsy
punches, syringes and needles, slides, containers with transport
media (700 ml [swab and punch biopsy samples], 300 ml [FNA
samples] CLS [cell lysis solution, Qiagen, Hilden, Germany] for
PCR samples) and data entry forms were provided to the study
sites [13,23,25,26,29,37–41].
Samples for PCR analysis were transported in CLS at ambient
temperature in an upright position in custom-made specimen
collection bags from the field to INH by DAHWT cars within a
maximum of 48 hours following sample collection. Upon arrival of
PCR samples at INH these were stored at 4–8uC until further
processing. Slides for microscopy were transported in slide boxes
at ambient temperature to CHR and subsequently to INH.
Laboratory diagnostics
Direct smears for microscopy were prepared from swab and
FNA samples at USPs or CHR and subjected to Ziehl-Neelsen
staining at CHR. Slides were analyzed according to the WHO
recommended grading system [42].
For PCR analysis DNA was prepared using the Gentra
Puregene DNA extraction kit (Qiagen, Hilden, Germany) with
minor modifications of the manufacturer’s protocol [21].
Three IS2404 PCR formats (dry-reagent-based [DRB] IS2404
PCR [INH], standard gel-based IS2404 PCR and IS2404 qPCR
[DITM]) were applied in this study. Briefly, for DRB-PCR the
oligonucleotides MU5 and MU6 were lyophilized in reaction
tubes. Illustra PuReTaq Ready-To-Go PCR beads (GE Health-
care, Munich, Germany) were added and dissolved in water before
adding template DNA [21,25,26]. Standard IS2404 PCR was
performed according to the protocol described by Stinear et al.
[15,17]. IS2404 qPCR was performed as recently described using
a BioRad CFX96 real-time PCR detection system [27,43]. All
PCR assays included negative extraction controls, positive,
negative (no template) and inhibition controls.
Stepwise approach to implementation of diagnostic
laboratory facilities at INH
Implementation of diagnostic laboratory facilities at INH was
accomplished in several phases. Before launching the national
BUD reference laboratory at INH in January 2011, laboratory
assessment of diagnostic samples from ‘‘BuruliVac’’ study partic-
ipants was conducted at CHR (microscopy) and DITM (PCR)
respectively (‘‘initial phase’’ [phase I] from September 2010
through December 2010). To implement standardized BUD
microscopy and PCR services at INH, all required equipment,
reagents and consumables were shipped to Togo by DAHWT and
installed under supervision of DITM staff from November through
December 2010. Subsequently, the transitional phase (phase II)
was initiated in January 2011. All relevant laboratory procedures
were defined in SOPs (SOP S1–S4). An initial laboratory training
workshop was held by DITM staff, and INH staff was familiarized
with the principles of standardized documentation of samples and
corresponding results (laboratory data entry forms, web-based
database), the flow of information between the participating
laboratories, and the principles of EQA as outlined below. Whereas
during the transitional phase from January 2011 through April 2012
parallel diagnostic samples of all study participants were simulta-
neously subjected to PCR analysis at INH and DITM, the final
phase (phase III) of PCR implementation (ongoing since May 2012)
provides for diagnostic PCR conducted independently at INH
accompanied by EQA on DNA extracts at DITM. (Figure 1)
External Quality Assurance
During the initial phase EQA was conducted for microscopy
only. Slides were read at CHR by two readers, forwarded to DITM
for blinded re-reading [13], and both, CHR and DITM results were
entered in the web-based database. In case of discordant results
between CHR and DITM, slides were subjected to a second re-
reading at DITM which determined the consensus result.
During the transitional phase CHR conducted the first reading of
slides by two readers, entered a consensus result in a specific result
form (Form S1), and forwarded slides and forms to INH (first
controller) for blinded re-reading. INH consensus results were also
determined by two readers and entered in a specific result form
(Forms S2). Finally, CHR and INH results were entered in the web-
based database by INH data managers. In case of discordant results
the respective slides were re-read by both, CHR and INH staff, and a
consensus result was determined. Subsequently, slides were
forwarded to DITM (second controller) for blinded re-reading,
and DITM results were entered in the web-based database. Slides
with discordant results between DITM and INH were re-read by
DITM and INH staff during DITM supervisory visits.
For EQA of PCR all clinical samples were collected in pairs
and were simultaneously tested at INH (DRB-PCR) and DITM
(standard IS2404 PCR, confirmatory IS2404 qPCR on negative
samples). Results were entered in the web-based database. In
National Reference Laboratory for BUD in Togo
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case of discordant results both laboratories repeated PCR
analyses. If the result did not alter, DNA extracts of the
respective samples were exchanged and re-tested at both
laboratories.
Parameters to determine performance of CHR and INH
In accordance with a previous study on EQA for the laboratory
diagnosis of BUD in Ghana [23] microscopy positivity rates (i.e.
number of positive samples divided by the total number of samples
tested) at CHR, INH, and DITM, PCR positivity rates at INH
and DITM, rates of false negative and false positive results
compared to DITM results and inter-laboratory concordance rates
between CHR/INH/DITM for microscopy and INH/DITM for
PCR were determined for the initial and transitional phases. In
addition, case confirmation rates (i.e. number of laboratory
confirmed BUD patients divided by the total number of suspected
BUD cases) were determined for CHR (microscopy), INH and
DITM (microscopy and PCR).
Parameters to assess the impact on BUD control
To assess the impact of the local reference laboratory and
continuous EQA measures on BUD control, the clinical param-
eters ‘‘type of lesion’’, ‘‘category of lesion’’, and ‘‘duration of
disease before clinical diagnosis’’ (i.e. the mean duration of disease
in days based on the time from first recognition of clinical
symptoms by patients and availability of the clinical diagnosis
BUD) were analyzed and data obtained from the current study
cohort from January 2011 through April 2012 after implementa-
tion of the national reference laboratory were compared to data
obtained in a previous study from September 2007 through
December 2010.
Feedback to CHR and field staff
INH forwards all laboratory results directly to CHR, the
subsequent reporting chain includes regional CLTs, district CLTs,
ICPs, and ASCs. Laboratory confirmed BUD patients are
subjected to treatment. In case of negative laboratory results in
general the treatment decision is referred to the BUD team. For
the purpose of documentation, lesions of all confirmed patients are
photographed; the material is available for training and sensitiza-
tion activities.
Statistical analysis
The study design was non-randomized and cross-sectional.
Figure 1. Stepwise approach to implementation of diagnostic laboratory facilities at INH. Figure 1 describes the process of
implementation of diagnostic laboratory facilities at INH in three phases and the flow of samples as well as the flow of feedback between the
Department for Infectious Diseases and Tropical Medicine (DITM), Ludwig-Maximilians-University, Munich, Germany, the ‘‘Institut National d’Hygie`ne’’
(INH), Lome´, Togo, the ‘‘Centre Hospitalier Re´gional Maritime’’ (CHR), Tse´vie´, Togo, and field staff. BUD, Buruli ulcer disease; CLT, ‘‘Controˆleur Le`pre-
TB-Buruli’’ – district controllers; DRB-PCR, dry-reagent-based IS2404 PCR; EQA, external quality assurance; MIC, microscopic detection of acid fast
bacilli by Ziehl-Neelsen staining; PCR, polymerase chain reaction; qPCR, IS2404 quantitative real-time PCR; standard PCR, conventional gel-based
IS2404 PCR; USP, ‘‘Unite´ de Soins Pe´riphe´rique’’ – peripheral health posts.
doi:10.1371/journal.pntd.0002011.g001
National Reference Laboratory for BUD in Togo
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Approximative tests (x2-tests) including analysis for linear trends
in proportions and t-tests as parametric test were conducted using
Stata software, version 9.0. (Stata Corporation, College Station,
TX) and EpiInfo, version 3.3.2. (Centers for Disease Control and
Prevention, Atlanta, GA). Significant differences were defined as
not overlapping of 95 percent confidence intervals (95% CI) of
proportions.
Results
Training measures for field staff and outcome of
outreach programs
Altogether 16 workshops with 559 participants (‘‘CLT teams’’ as
well as other medical and paramedical staff) addressing clinical
picture, laboratory diagnosis and treatment of BUD were held in the
regions ‘‘Maritime’’ and ‘‘Central’’. Since 2011, the CLT teams
conducted sensitization activities in 1027 villages and screened a
population of approximately 110,000. Out of 192 persons with
lesions suspicious for BUD identified in the field, 82 suspected BUD
cases were finally referred to USPs or CHR. (Table 1)
Number of samples analyzed by microscopy
During the initial phase, 17 slides (swab, n = 6; FNA, n = 11)
obtained from 16 suspected BUD cases (ten non-ulcerative lesions: one
FNA sample per lesion; six ulcerative lesions, one swab sample per
lesion and one additional FNA sample from one lesion with scarred
edges) were analyzed at CHR and subjected to EQA at DITM.
Table 1. Geographic origin, type and classification of lesions of clinically suspected and laboratory confirmed BUD patients.
Region District
Clinically
suspected BUD
cases Laboratory confirmed BUD patients
a
Total per
districtb
Non-ulcerative
lesions
Ulcerative
lesions Category Ic Category IId Category IIIe
Central Sotouboua 4.9% (4/82) 0% (0/64) 0% (0/64) 0% (0/64) 0% (0/64) 0% (0/64) 0% (0/64)
Maritime Golfe 2.4% (2/82) 1.6% (1/64) 0% (0/64) 1.6% (1/64) 0% (0/64) 0% (0/64) 1.6% (1/64)
Yoto 48.8% (40/82) 57.8% (37/64) 31.3% (20/64) 26.6% (17/64) 32.8% (21/64) 18.8% (12/64) 6.3% (4/64)
Vo 1.2% (1/82) 1.6% (1/64) 1.6% (1/64) 0% (0/64) 1.6% (1/64) 0% (0/64) 0% (0/64)
Zio 36.6% (30/82) 34.4% (22/64) 18.8% (12/64) 15.6% (10/64) 9.4% (6/64) 18.8% (12/64) 6.3% (4/64)
Plateauxf Amou´ 1.2% (1/82) 0% (0/64) 0% (0/64) 0% (0/64) 0% (0/64) 0% (0/64) 0% (0/64)
Anie´ 1.2% (1/82) 1.6% (1/64) 0% (0/64) 1.6% (1/64) 0% (0/64) 1.6% (1/64) 0% (0/64)
Haho 1.2% (1/82) 0% (0/64) 0% (0/64) 0% (0/64) 0% (0/64) 0% (0/64) 0% (0/64)
Ogou 1.2% (1/82) 1.6% (1/64) 0% (0/64) 1.6% (1/64) 0% (0/64) 0% (0/64) 1.6% (1/64)
Savanesf Dapaong 1.2% (1/82) 1.6% (1/64) 0% (0/64) 1.6% (1/64) 0% (0/64) 1.6% (1/64) 0% (0/64)
Total 100% (82/82) 100% (64/64) 51.6% (33/64) 48.4% (31/64) 43.8% (28/64) 40.6% (26/64) 15.6% (10/64)
Table 1 shows the geographic origin of all suspected and confirmed BUD patients, and type/category of lesions of confirmed BUD patients who presented from
September 2010 through April 2012 in Togo. More than 85% of confirmed BUD patients originated from the districts Yoto and Zio of region ‘‘Maritime’’.
aPatients were confirmed by dry-reagent-based IS2404, standard gel-based IS2404 PCR and/or IS2404 quantitative real-time PCR. BUD, Buruli ulcer disease.
bNumber of confirmed BUD patients per district.
cCategory I, single lesion ,50 mm in diameter.
dCategory II, single lesion between 50 and 150 mm in diameter.
eCategory III, single lesion .150 mm in diameter or multiple lesions, osteomyelitis or lesions at critical sites.
fLaboratory confirmed BUD patients were referred to CHR, Tse´vie´, for antimycobacterial treatment.
doi:10.1371/journal.pntd.0002011.t001
Table 2. Clinical samples analyzed by microscopy for M. ulcerans.
No. of suspected
BUD cases No. of swab samples subjected to MIC
a No. of FNA samples subjected to MICa Totalb
CHR/DITM CHR/INH/DITM CHR/DITM CHR/INH/DITM
Phase Ic 16 6 N/A 11 N/A 17
Phase IId 66 N/A 24 N/A 48 72
Total 82 30 59 89
Table 2 indicates all slides prepared from swab or FNA samples and subjected to Ziehl-Neelsen staining at ‘‘Centre Hospitalier Re´gional’’ (CHR) for the detection of acid
fast bacilli. Slides were analyzed consecutively at CHR and the Department of Infectious Diseases and Tropical Medicine (DITM), Ludwig-Maximilians-University during
initial phase (phase I) or CHR, at the ‘‘Institut National d’Hygie`ne’’ (INH) and DITM during transitional phase (phase II). N/A, not applicable.
aMIC, microscopic detection of acid fast bacilli.
bTotal, number of slides prepared from swab and FNA samples and subjected to reading at CHR/DITM or CHR/INH/DITM.
cPhase I, initial phase of implementation of the national reference laboratory at INH from September 2010 through December 2010; slides were read at CHR and
forwarded via DAHWT to DITM for EQA.
dPhase II, transitional phase of implementation of the national reference laboratory at INH from January 2011 through April 2012; slides were read at CHR, followed by
blinded re-reading at INH and DITM.
doi:10.1371/journal.pntd.0002011.t002
National Reference Laboratory for BUD in Togo
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During the transitional phase, 72 slides (swab, n = 24; FNA, n = 48)
obtained from 66 suspected BUD cases (38 non-ulcerative lesions:
one FNA sample per lesion; 28 ulcerative lesions: one swab sample
each from 18 lesions, one swab and one FNA sample each from six
lesions, one FNA sample each from four lesions) were analyzed at
CHR and subjected to EQA at INH and DITM. (Table 2)
External quality assurance of microscopy
During the initial phase positivity rates of microscopy were
41.2% (7/17) at CHR and 47.1% (8/17) at DITM with 5.9% (1/
17) false negative results from CHR, and an inter-laboratory
concordance rate of 94.1% (16/17) between CHR and DITM.
During the transitional phase positivity rates of microscopy were
47.2% (34/72) at CHR, 48.6% (35/72) at INH and 55.6% (40/72)
at DITM. The rate of false negative test results was 9.7% (7/72) at
CHR and 6.9% (5/72) at INH, and 1 out of 72 slides (1.4%) was
read false positive at CHR. Concordance rates between labora-
tories were 94.4% (68/72) for CHR/INH, 88.9% (64/72) for
CHR/DITM and 93.1% (67/72) for INH/DITM.
The concordance rate between CHR and DITM for both
phases was 89.9% (80/89). (Table 3)
Number of samples analyzed by PCR
During the initial phase, 35 samples (swab, n = 6; FNA, n = 16;
punch biopsy, n = 13) obtained from 16 suspected BUD cases were
subjected to standard PCR at DITM, all negative samples (n = 12)
were additionally subjected to qPCR.
During the transitional phase, 99 sample pairs (swab, n = 33;
FNA, n = 44; punch biopsy, n = 22) obtained from 66 suspected
BUD cases were subjected to PCR at INH and DITM, which equals
a mean rate of 3.0 (198/66) samples tested per patient. All negative
samples (n = 30) were additionally subjected to qPCR. (Table 4)
External quality assurance of PCR
During the initial phase the positivity rate of standard PCR at
DITM was 65.7% (23/35). Confirmation of two out of 12 negative
samples by qPCR provided an additional diagnostic yield of 5.7%.
During the transitional phase positivity rates of conventional
PCR assays were 65.7% (65/99) at INH and 69.7% (69/99) at
DITM. The rate of false negative test results at INH was 4.0% (4/
99; 1 swab sample and 3 FNA samples), there were no false
positive results, and the inter-laboratory concordance rate was
96.0% (95/99). Confirmation of 6 out of 30 negative samples by
qPCR provided an additional diagnostic yield of 6.1%. (Table 5)
Laboratory confirmed patients
The case confirmation rates for microscopy were 31.3% (5/16) at
CHR and 37.5% (6/16) at DITM during the initial phase, and
43.9% (29/66) at CHR, 47.0% (31/66) at INH, and 53.0% (35/66)
at DITM during the transitional phase. In total 50.0% (41/82) of the
suspected BUD cases were confirmed by microscopy. (Table 3)
The case confirmation rates for PCR were 75.0% (12/16) at
DITM during the initial phase, and 71.2% (47/66) at INH and
78.8% (52/66) at DITM (including two cases additionally confirmed
by qPCR) during the transitional phase. In total 78.1% (64/82) of
the suspected BUD cases were confirmed by PCR. (Table 5)
Epidemiological baseline and treatment data of
confirmed BUD cases
Out of 64 laboratory confirmed BUD patients, 51.6% (33/64) had
non-ulcerative lesions (plaque, n = 17; nodule, n = 10; papule, n = 1;
edema, n = 5) and 48.4% (31/64) had ulcerative lesions, 48.4% (31/
64) were male, and 48.4% (31/64) were in age group 5–14 years (age
range 2–68 years, mean 18.1 years, median 13 years). Figure 2
The confirmed BUD patients originated from four districts of
region ‘‘Maritime’’ (Yoto, n = 37; Zio, n = 22; Vo, n = 1; Golfe,
n = 1), two districts of region ‘‘Plateaux’’ (Anie´, n = 1; Ogou, n = 1)
and one district of region ‘‘Savanes’’ (Dapaong, n = 1). The
categories of lesions according to WHO classification [3] were as
follows: 43.8% (28/64) category I, 40.6% (26/64) category II and
15.6% (10/64) category III. (Table 1)
All patients with suspected BUD (n = 82) who presented in Togo
during the study period were included (no refusals to participate)
Table 4. Clinical samples analyzed by PCR for M. ulcerans.
No. of suspected BUD
cases Samples analyzed by PCR
Laboratory IS2404 PCR assay Swaba FNAb Punchc Total
Phase Id 16 DITM Standard PCR 6 16 13 35
qPCRe 3/6 6/16 3/13 12/35
Totalf 6 16 13 35
Phase IIg 66 INH DRB PCR 33 44 22 99
DITM Standard PCR 33 44 22 99
qPCRe 6/33 15/44 9/22 30/99
Totalf 66 88 44 198
Total -phase I and II 82 72 104 57 233
Table 4 indicates all samples tested by PCR at IHN and DITM. During the initial phase (phase I) samples were analyzed by standard gel-based IS2404 PCR at DITM. During
the second phase (phase II) parallel samples were subjected to IS2404 dry-reagent based (DRB) PCR at INH and standard IS2404 PCR at DITM. During both phases all
samples tested negative in standard PCR were subjected to re-testing by IS2404 quantitative real-time PCR (qPCR) at DITM.
aSwab, DNA extracts prepared from swab samples.
bFNA, DNA extracts prepared from fine-needle aspirate samples.
cPunch, DNA extracts prepared from 3 mm punch biopsy samples.
dPhase I, initial phase of implementation of the national reference laboratory at INH from September through December 2010.
eOnly samples tested negative in standard IS2404 PCR were subjected to IS2404 qPCR at DITM.
fTotal amount of samples tested by DRB- and Standard PCR during the corresponding phases.
gPhase II, transitional phase of implementation of the national reference laboratory at INH from January 2011 through April 2012.
doi:10.1371/journal.pntd.0002011.t004
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and clinical samples were collected and analyzed from all of them.
All laboratory confirmed BUD patients (n = 64) received a full
course of treatment with rifampicin and streptomycin; in addition,
six patients, despite negative laboratory results, were subjected to
antimycobacterial treatment based on strong clinical suspicion of
BUD. Although no regular outreach activities were conducted in
region ’’Plateaux’’ and ’’Savanes‘‘ patients from both regions were
referred to CHR for treatment.
Impact on quality of BUD control
The number of patients with non-ulcerative lesions among all
PCR-confirmed patients increased significantly (p,0.01) from
37.0% (as determined for the study cohort from 2007–2010, 119
patients) to 50.0% (current study cohort from January 2011
through April 2012, 52 patients).
Compared to the previous study category I lesions increased
from 36.9% (95% CI: 28.3–45.6) to 44.2% (95% CI: 30.7–57.7),
category II lesions increased from 32.8% (95% CI: 24.3–41.2) to
36.6% (95% CI: 23.5–49.6) and category III lesions decreased
from 30.3% (95% CI: 22.0–38.5) to 19.2% (95% CI: 8.5–29.9).
The mean duration of disease before clinical diagnosis
decreased from 51.8 (95% CI: 19.0–84.7) to 35.0 (95% CI:
23.5–46.5) days (no significant difference) among patients with
non-ulcerative lesions, and significantly from 182.6 [95% CI:
119.2–245.9] to 82.1 [95% CI: 51.3–112.8] days among patients
with ulcerative lesions. (Table 6)
Discussion
Laboratory confirmation of suspected BUD cases, in particular
by molecular diagnostic tests, plays a crucial role for clinical
management, disease control and research on M. ulcerans.
To achieve the targeted PCR confirmation rate of more than
50% of suspected BUD cases worldwide, WHO has set up a
network of external and local PCR reference laboratories [36].
Whereas until the early 2000s laboratory diagnostic services for
endemic countries were mainly provided by external reference
laboratories, until 2011 six African countries (Ivory Coast, Ghana,
Benin, Cameroon, Central African Republic, Democratic Repub-
lic of Congo) installed their own reference laboratories upon
increasing demand for local diagnostic capacity [6,10,11,18,20–
26,29,30,32,37,44–46]. Due to the absence of laboratory facilities
a number of countries still require support from external reference
laboratories; in general however, the role of external reference
laboratories has shifted to development of improved laboratory
techniques for application in endemic countries, technical support
and training of local laboratory staff, as well as external quality
assurance for newly established reference laboratories [6,11,21,23–
32,37–40,43].
As well known from other studies, the implementation of
reference level laboratory facilities necessitates multiple provisions
in terms of logistics, trained personnel and quality management
[11,23,47,48]. In the case of Togo, extensive preparatory work
conducted in the context of previous research projects by
DAHWT and DITM [13], vast expertise gained from a long-
standing cooperation with partners in Ghana [21,23,25,26,29,40],
as well as continuous exchange of information with other
‘‘BuruliVac’’ partners [6,32] facilitated the implementation of a
national reference laboratory considerably.
Excellent technical skills of INH laboratory staff in conventional
and molecular microbiological diagnostic techniques allowed starting
laboratory training at an advanced level. All training activities took
place at INH; basic laboratory training according to the concept of
Figure 2. Age distribution of laboratory confirmed BUD patients. Age distribution of 64 laboratory confirmed BUD patients recruited from
September 2010 through April 2012. The age of all patients was known and 48.4% (31/64) were in age group 5–14 years. The age range was 2–68
years with a mean of 18.1 years and a median of 13 years.
doi:10.1371/journal.pntd.0002011.g002
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short-term ‘‘training of trainers’’ workshops in Europe as successfully
applied by other external reference laboratories was not required.
In consideration of the existing quality management systems at
DITM and INH, special emphasis was given to standardization of all
relevant procedures. SOPs defined the interaction of the laboratory
with external partners in the field and the external reference
laboratory in Germany, as well as all processes within the laboratory,
and granted a smooth workflow from the beginning of the project.
Standardized documentation of all analyses and results in standard-
ized laboratory forms and the project-specific web-based database
facilitated rapid retracing of errors for local and external reference
laboratory and allowed targeted training measures.
To measure the quality of diagnostics conducted at INH, we
determined concordance rates between local and external
reference laboratories. Compared to a previous study [13], the
concordance rate for microscopic analysis between CHR and
DITM (initial and transitional phase) increased from less than
70% to 90%, and the concordance rate between INH and DITM
was over 90% during the transitional phase, suggesting a high
standard of microscopy at both, CHR and INH. Compared to
previous findings [13], also the case confirmation rate for
microscopy increased from 30% (CHR) to 43% (CHR) and
47% (INH), respectively. Likewise, concordance rates between
INH and DITM for PCR of swab and punch biopsy samples were
over 95%. In this study, instead of testing the same sample
subsequently at both laboratories, sample pairs were collected and
one sample each was sent to DITM and INH to allow quality
control for both, extraction efficiency and amplification. As
Table 6. Impact of local reference laboratory and external quality assurance measures on BUD control.
Year of clinical
presentation 2007 2008 2009 2010 2011 2012 2007–2010 2011–2012
No. of confirmed BUD
patientsa
10 38 33 38 41 11 119 52
No. of confirmed patients
with non-ulcerative lesion
3 6 12 23 21 5 44 26
No. of confirmed patients
with ulcerative lesions
7 32 21 15 20 6 75 26
Rate of confirmed BUD
patients with non-ulcerative
lesionsb
30.0% (3/10) 15.8% (6/38) 36.4% (12/33) 60.5% (23/38) 51.2% (21/41) 45.5% (5/11) 37.0% (44/119) 50.0% (26/52)
Rate of confirmed BUD
patients – category Ic
20.0% (2/10) 50.0% (19/38) 24.2% (8/33) 39.5% (15/38) 46.3% (19/41) 36.4% (4/11) 36.9% (44/119) 44.2% (23/52)
95% confidence interval 0–44.8 34.1–65.9 9.6–38.9 23.9–55.0 31.1–61.6 7.9–64.8 28.3–45.6 30.7–57.7
Rate of confirmed BUD
patients – category IId
30.0% (3/10) 36.8% (14/38) 30.3% (10/33) 31.6% (12/38) 34.2% (14/41) 45.5% (5/11) 32.8% (39/119) 36.6% (19/52)
95% confidence interva 1.6–58.4 21.5–52.2 14.6–46.0 16.8–46.4 19.6–48.7 16.0–74.9 24.3–41.2 23.5–49.6
Rate of confirmed BUD
patients – category IIIe
50.0% (5/10) 13.2% (5/38) 45.5% (15/33) 29.9% (11/38) 19.5% (8/41) 18.1% (2/11) 30.3% (36/119) 19.2% (10/52)
95% confidence interval 19.0–81.0 2.4–23.9 28.5–62.4 14.5–43.4 7.4–31.6 0–41.0 22.0–38.5 8.5–29.9
Mean duration of disease
before clinical diagnosis
in daysf
Patients with non-ulcerative
lesions
318.7 74.0 25.8 24.8 30.3 54.6 51.8 35.0
95% confidence interval 0–718.2 16.7–131.4 12.6–38.9 16.6–33.1 18.7–41.9 23.2–86.0 19.0–84.7 23.5–46.5
Patients with ulcerative
lesions
386.0 239.2 107.6 71.8 87.5 64.0 182.6 82.1
95% confidence interval 78.3–693.7 118.2–360.1 59.6–55.6 45.6–98.0 48.0–27.0 45.0–83.0 119.2–245.9 51.3–112.8
All patients 365.8 213.1 77.8 43.4 58.2 59.7 134.2 58.5
95% confidence interval 130.8–600.8 109.3–316.9 44.3–111.3 29.9–56.8 36.4–80.0 42.8–76.6 91.1–177.4 41.1–76.0
Table 6 shows analyses of clinical parameters (i.e. ‘‘type of lesion’’ and ‘‘duration of disease before clinical diagnosis’’) among PCR confirmed BUD new cases to assess
impact of the local reference laboratory and external quality assurance measures on BUD control in Togo. Therefore, data from a previous study (September 2007
through December 2010) prior to implementation of the national reference laboratory at INH were analyzed and compared with data obtained in the present study
(January 2011 through April 2012). Analysis for linear trends in proportions revealed a significant (p,0.01) increase of patients presenting with non-ulcerative lesions
from 37.0% (2007–2010) to 50.0% (2011–2012). The mean duration of disease among patients with non-ulcerative lesions before presentation and establishment of
clinical diagnosis decreased not significantly from 51.8 (95% CI: 19.0–84.7) to 35.0 (95% CI: 23.5–46.5) days during the two observation periods. However, the mean
duration of disease among patients with ulcerative lesions before presentation of patients and establishment of clinical diagnosis decreased significantly from 182.6
(95% CI: 119.2–245.9) to 82.1 (95% CI: 51.3–112.8) days during the two observation periods. Furthermore, analysis of the development of categories of lesions showed a
statistically non significant decrease from 30.3% (95% CI: 22.0–38.5) to 19.2% (95% CI: 8.5–29.9) of category III lesions. BUD, Buruli ulcer disease; CI, confidence interval.
aNumber of confirmed BUD patients, laboratory confirmation was conducted by standard IS2404 PCR, IS2404 DRB-PCR and/or IS2404 qPCR.
bRate of confirmed BUD patients with non-ulcerative lesions among all confirmed BUD patients per observation period.
cCategory I, single lesion ,50 mm in diameter.
dCategory II, single lesion between 50 and 150 mm in diameter.
eCategory III, single lesion .150 mm in diameter or multiple lesions, osteomyelitis or lesions at critical sites.
fMean duration of disease in days based on the time from first recognition of clinical symptoms by patients and availability of the clinical diagnosis ‘‘BUD’’. Only data
from PCR confirmed BUD patients were analyzed.
doi:10.1371/journal.pntd.0002011.t006
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already observed in other studies, parallel samples – even if
collected from the same site of the lesion - may show an
inhomogeneous distribution of mycobacteria and may increase the
normal inter-laboratory variation regularly observed for weakly
positive samples ([23,49], unpublished data). Therefore, the
findings suggest high quality of PCR conducted at INH. With
93% the inter-laboratory concordance rate for FNA samples was
slightly lower which may be attributable to dividing FNA samples
in two pieces for microscopy and PCR at INH (whereas the entire
parallel sample was subjected to PCR at DITM). Consequently,
also the case confirmation rate at INH was a little lower (71%)
than at DITM (76%). Future EQA of PCR diagnostics is
conducted on DNA extracts only, therefore both confounders
(sample pairs and divided samples) are excluded.
In addition to conventional gel-based PCR, DITM applied
IS2404 qPCR on negative samples which resulted in laboratory
confirmation of two additional cases. As real-time PCR facilities
are available at INH, implementation of IS2404 qPCR is
envisaged for 2013. Laboratories in endemic countries without
access to real-time PCR may consider forwarding at least samples
from patients with strong clinical suspicion but negative conven-
tional PCR result to an external reference laboratory for
confirmatory IS2404 qPCR.
The study also attempted to measure the impact of local
laboratory capacity and quality management on BUD control.
The increase of the rate of non-ulcerative lesions by 13%, the
significant reduction of the diagnostic delay by more than 100 days
for patients with ulcerative lesions as compared to a previous study
[13] and the reduction of category III lesions from 30.3% to
19.2% may be attributed to an extended quality management
system also comprising patient related procedures outside the
laboratory and intensified training measures.
Already during the previous study period from 2007 through 2010
CLTs, ICPs, ASCs and other field staff had been trained in 28
workshops with 152 participants. Since 2011, however, training
measures achieved a roughly five-fold increase in coverage, and
training of teams instead of individuals resulted in a multiplier effect
in terms of knowledge transfer which became noticeable also in areas
without regular outreach activities through referral of patients to
CHR. The availability of trained CLT teams in 11 districts, in
particular the ASCs, increased the coverage of sensitization activities
and allowed to conduct extensive ‘‘information, education and
communication’’ (IEC) campaigns under the guidance of DAHWT
and PNLUB-LP in regions ‘‘Maritime’’ and ‘‘Central’’ accompanied
by regular outreach activities to identify suspected BUD cases in the
field. Finally, supervision of CLT teams by the CHR BUD team in
terms of re-examining these patients provided continuous on-site
training for CLT teams and enhanced the diagnostic skills of all field
staff involved. Feed- back of laboratory results through a newly
established reporting chain from INH to community level not only
provides the basis for targeted case finding activities in the
environment of confirmed patients, but is also conceived as
confidence-building measure by ASCs as well as patients and their
families. Altogether, the outreach system implemented in 2011
allowed to realize key components of BUD control in the field of early
case detection, diagnosis and treatment as defined by the WHO [7],
and more than 90% of BUD cases are currently detected through
active case finding (opposed to roughly 60% in the previous study).
Whereas these outreach activities resulted in a constant flow of
diagnostic samples from suspected BUD cases from peripheral
health facilities in region ‘‘Maritime’’ via the regional hospital
(CHR) to INH, and the first cases from region ‘‘Plateaux’’ and
‘‘Savanes’’ have been identified, to date no cases from region
‘‘Central’’ have been confirmed.
Since June 2012, a cooperation agreement between the ‘‘Faculte´
Mixte de Me´de´cine et de Pharmacie’’ of the University of Lome´,
Togo and the Faculty of Medicine of the Ludwig-Maximilians-
University, Munich, Germany, has reinforced the existing diagnostic
network through initiation of a collaboration with the ‘‘Laboratoire
de Biologie Mole´culaire et d’Immunologie’’ (BIOLIM), ‘‘De´parte-
ment des Sciences Fondamentales et Biologiques’’. BIOLIM will
support ongoing EQA measures in the field of quality control,
academic and in-service training of local laboratory staff, thus
contribute to maintaining sustainable standards in laboratory
confirmation of BUD. Furthermore, access to a nationwide
laboratory network established in the context of research on HIV
and other infectious diseases conducted by BIOLIM will enable
operational research on decentralised diagnostics and increase the
efficiency of BUD control. [7,48,50]
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